We’ve all carried this torch longer than anyone thought possible — not because it was easy, but because patients don’t get to walk away.

CCR5 is not a single asset story. It’s a platform with reach across oncology, HIV, neurology, and inflammation. That kind of science doesn’t get brushed aside for pocket change, because patients are not pocket change. They are families, friends, and futures.

Shareholders have stood firm because patients have had no choice but to stand firm. The right partner will see the full value and be welcomed. The wrong deal will not stand.

This isn’t anger. This is clarity.